touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes.
His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY’ was given at UEG Week Virtual, 3-5 Oct 2021.
Questions
- What are the advantages of the Partial Mayo Clinic Score (pMCS) as an outcome measure in clinical trials for ulcerative colitis? (0:17)
- What were the aims and design of the SELECTION study? (1:42)
- What were the findings in terms of pMCS? (3:07)
- What are the clinical implications of these findings, and where do you see filgotinib sitting in the treatment paradigm for UC? (3:46)
Disclsoures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare and non-financial support from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
